Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors
- 9 February 1999
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 366 (2-3), 293-300
- https://doi.org/10.1016/s0014-2999(98)00896-6
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study GroupJAMA, 1997
- Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervationBrain Research, 1996
- Comparative Review of Dopamine Receptor Agonists in Parkinsonʼs DiseaseCNS Drugs, 1996
- The two-state model of receptor activationTrends in Pharmacological Sciences, 1995
- Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell lineEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Characteristics of stably expressed human dopamine D1a and D1b receptors: Atypical behavior of the dopamine D1b receptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- PergolideDrugs, 1990
- Affinity Shifts Induced by Cations Do Not Reliably Predict the Agonistic or Antagonistic Nature of Ligands at Brain Dopamine ReceptorsJournal of Neurochemistry, 1987
- Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivoLife Sciences, 1986